The 'Golden Standard' for Serological Detection of Nasopharyngeal Carcinoma
The product was published in the top medical journal The New England Journal of Medicine in 2023, was selected into the 'Important Medical Advances in China in 2023', participated in and won the Second Prize of the National Science and Technology Progress Award in 2023, and was included in the 'Guidelines for the Diagnosis and Treatment of Nasopharyngeal Carcinoma 2024' of the Chinese Society of Clinical Oncology (CSCO).
Core Advantages
Earlier Detection
The detection rate of early nasopharyngeal carcinoma is as high as 94%, enabling early detection, diagnosis, and treatment of the disease.
More Accurate
The specificity for healthy people is over 98%, greatly reducing the false positive rate and alleviating the psychological burden of the examinees.
More Reliable
The positive predictive value of a single indicator is 2.3 times higher than the existing scheme, and the positive predictive value of the P85-Ab combined with the double-antibody scheme is increased by 7 to 10 times. The detection efficiency is significantly improved, reducing the waste of medical resources.
Screening Performance Indicators
94%
Early Detection Rate
98%+
Specificity
7~10 Times
Increase in Positive Predictive Value
Auxiliary Diagnosis Performance Indicators
93.3%
Sensitivity
97.4%+
Specificity
95.7%
Agreement Rate with Biopsy
Application Scenarios
Opportunistic Screening: Cancer Prevention Physical Examination
Opportunistic Screening: Physical Examination Focusing on Nasal Health
Mass Population Screening: Suitable for mass population screening in high and medium-incidence areas of nasopharyngeal carcinoma, especially in southern provinces such as Guangdong, Guangxi, Hainan, Fujian, Hunan, and Jiangxi.
Auxiliary/Differential Diagnosis
Used for the auxiliary diagnosis and differential diagnosis of suspected nasopharyngeal carcinoma patients in the otorhinolaryngology department of medical institutions.
Treatment Effect Monitoring
Used for the evaluation of the treatment effect and postoperative follow-up of nasopharyngeal carcinoma patients.
Solutions for Screening and Diagnosis of Nasopharyngeal Carcinoma
Tests for Nasopharyngeal Carcinoma Screening
P85-Ab (EB BNLF2b Antibody)
EB VCA-IgA
EB NA1-IgA
EB Zta-IgA
Provides a more comprehensive serological detection solution for nasopharyngeal carcinoma.
Wan Series Automatic Chemiluminescence Immunoassay Analyzer
An automatic chemiluminescence immunoassay analyzer specifically adapted for chemiluminescence detection tests such as P85-Ab.
Integrated Solution for Screening, Detection, Diagnosis, Reporting and Follow-up of Nasopharyngeal Carcinoma
An integrated serological detection solution for nasopharyngeal carcinoma that integrates screening, detection, diagnosis, reporting, and follow-up management.
For more information : wtexport@ystwt.com
Filing Number:(京)网药械信息备字（2025）第 00190 号
|
Copyright©Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
|
|
京公网安备11011402010353号 
Alibaba Cloud provides cloud computing and security services.|
It supports
|
Powered by CloudDream
|
Terms Of Use|
Privacy Statement